Skip to main content
SpringerLink
Log in

Therapy for Menopausal Symptoms During and After Treatment for Breast Cancer

Safety Considerations

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Breast cancer is the most common newly diagnosed cancer in women. Life-time risk in the US is 1 in 8 (13.2%), in the UK it is 1 in 9 and in Australia it affects 1 in 11 women, of whom approximately 27% will be premenopausal at the time of their diagnosis. Many of these women will experience a sudden menopause as a result of chemotherapy, endocrine therapy or surgical interventions. For these women, the onset of menopausal symptoms is often sudden and severe. The management of such symptoms remains controversial. Women experiencing menopausal symptoms after breast cancer should be encouraged to avoid identifiable triggers for their symptoms and to consider lifestyle modification as a means of controlling those symptoms. When such measures fail, non-hormonal treatments may also be considered. These include clonidine, gabapentin and some antidepressants. Randomised trials have shown a significant difference in the symptom relief associated with various selective serotonin reuptake inhibitors and selective serotonin and noradrenaline (norepinephrine) reuptake inhibitors compared with placebo. Many women elect to use non-prescription complementary therapies to alleviate their menopausal symptoms. Systematic reviews of phytoestrogens have, however, failed to demonstrate significant relief of menopausal symptoms.

More than 20 clinical trials have been conducted examining the relationship between postmenopausal hormone replacement therapy and breast cancer recurrence. The majority of these have been observational and have shown no increased risk of recurrence. However, the largest randomised trial that has thus far been conducted was recently halted because of a reported increase in the risk of recurrence amongst users of hormone replacement therapy. Tibolone, a selective tissue estrogen activity regulator, is a compound that exerts clinical effects both by receptor-mediated actions and tissue selective enzyme inhibition, and has been shown in preclinical studies to have different effects to estrogen on the breast. Although tibolone may prove safer than estrogen for long-term use in breast cancer survivors, the results of a large randomised trial are awaited to confirm this.

The decision on how best to manage menopausal symptoms must thus be made on an individual basis and after thorough discussion and evaluation of the risks and benefits of each potential intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. US National Cancer Institute. SEER Cancer Statistics Review, 1975-2002 [online]. Available from URL: http://www.seer.cancer.gov/csr/1975_2002 [Accessed 2005 Nov 9]

  2. Cancer Research UK Information Resource Centre. The incidence of breast cancer in the UK [online]. Available from URL: http://www.info.cancerresearchuk.org/cancerstats/types/breast/incidence/ [Accessed 2005 Nov 9]

  3. Australian Institute of Health and Welfare, Canberra, ACT. Cancer data registry 2002

  4. American Cancer Society. Breast cancer facts and figures. Atlanta (GA): ACS, 2004

  5. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17(8): 2365–70

    PubMed  CAS  Google Scholar 

  6. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999; 180(3 Pt 2): S312–6

    Article  PubMed  CAS  Google Scholar 

  7. Hersh AL, Stefanick ML, Stafford RS. National use of post menopausal hormone therapy: trends and response to recent evidence. JAMA 2004; 291: 47–53

    Article  PubMed  CAS  Google Scholar 

  8. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees. HABITS: a randomized comparison trial stopped. Lancet 2004; 363: 453–5

    Article  PubMed  CAS  Google Scholar 

  9. Fellowes D, Fallowfield LJ, Saunders CM, et al. Tolerability of hormone therapies for breast cancer. Breast Cancer Res Treat 2001; 66(1): 73–81

    Article  PubMed  CAS  Google Scholar 

  10. Schover L. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr 1994; 16: 177–82

    PubMed  Google Scholar 

  11. McCaughan SY. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996; 19: 308–19

    Article  Google Scholar 

  12. Baber RJ, O’Hara JL, Boyle FM. Hormone replacement therapy: to use or not to use? Med J Aust 2003; 178: 630–3

    PubMed  Google Scholar 

  13. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592: 52–86

    Article  PubMed  CAS  Google Scholar 

  14. Menopause WHO. Technical Report Series 866. In: Menopause; 1996: P236–42

  15. Freedman R. Physiology of hot flushes. Am J Hum Biol 2001; 13(4): 453–64

    Article  PubMed  CAS  Google Scholar 

  16. Stearns V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet 2002; 360: 1851–61

    Article  PubMed  CAS  Google Scholar 

  17. Montgomery JC, Studd J. Psychological and sexual aspects of the menopause. Br J Hosp Med 1991; 45(5): 300–2

    PubMed  CAS  Google Scholar 

  18. Bachmann G. Urogenital aging: an old problem newly recognized. Maturitas 1995; 22Suppl.: S1–5

    Article  PubMed  Google Scholar 

  19. Shaver JL. Women and sleep. Nurs Clin North Am 2002; 37(4): 707–18

    Article  PubMed  Google Scholar 

  20. MacLennan AH, Broadbent J, Lester S, et al. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2002; 288(1): CD002978

    Google Scholar 

  21. Writing group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) Trial. JAMA 1996; 276: 1389–296

    Google Scholar 

  22. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321–33

    Google Scholar 

  23. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701–12

    Google Scholar 

  24. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63

    Article  PubMed  CAS  Google Scholar 

  25. The RANZCOG Consensus Statement. Advice to medical practitioners regarding the use of postmenopausal hormone therapy [online]. Available from URL: http://www.ranzcog.edu.au [Accessed 2004 Aug]

  26. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 51,705 women with breast cancer and 108,411 without breast cancer. Lancet 1997; 350: 1047–59

    Google Scholar 

  27. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of 9 prospective studies. J Natl Cancer Inst 2002; 94: 606–16

    Google Scholar 

  28. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with Raloxifene. JAMA 2002; 287: 216–20

    Article  PubMed  CAS  Google Scholar 

  29. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths amongst 75,000 women. Lancet 1992; 339: 1–15

    Google Scholar 

  30. Early Breast Cancer Trialists Collaborative Group. Bilateral oophorectomy as a treatment for breast cancer recurrence: ovarian ablation in early breast cancer. Overview of the randomized trials. Lancet 1996; 348: 1189–96

    Google Scholar 

  31. Key T, Pike M. The role of estrogens and progestins in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29–43

    Article  PubMed  CAS  Google Scholar 

  32. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498–508

    Article  PubMed  CAS  Google Scholar 

  33. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2002; 360: 942–4

    Article  PubMed  Google Scholar 

  34. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91

    Article  PubMed  CAS  Google Scholar 

  35. Ross RK, Paganini-Hill A, Wan PC, et al. Effects of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32

    Article  PubMed  CAS  Google Scholar 

  36. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152(10): 950–64

  37. Magnusson C, Persson I, Adami HO. Effect of hormone replacement therapy on breast cancer risk: estrogen plus progestin. J Natl Cancer Inst 2000; 92: 1183–4

    Article  PubMed  CAS  Google Scholar 

  38. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 593–600

    PubMed  CAS  Google Scholar 

  39. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 289: 3243–53

    Article  PubMed  CAS  Google Scholar 

  40. Beral V. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27

    Article  PubMed  CAS  Google Scholar 

  41. Schapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004; 7(1): 3–7

    Article  Google Scholar 

  42. Powles TJ, Hickish T, Casey S, et al. Hormone replacement therapy after breast cancer. Lancet 1993; 342: 60–1

    Article  PubMed  CAS  Google Scholar 

  43. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372–5

    Article  PubMed  CAS  Google Scholar 

  44. Dhodapkar MV, Ingle JN, Ahmann DL. Oestrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995; 75: 43–36

    Article  PubMed  CAS  Google Scholar 

  45. Peters G, Jones S, Decker D, et al. Oestrogen replacement therapy in breast cancer patients. Proc Am Soc Clin Oncol 1996; 15: 121

    CAS  Google Scholar 

  46. Decker D, Cox T, Burdakin J, et al. Hormone replacement therapy in breast cancer survivors. Proc Am Soc Clin Oncol 1996; 15: 136

    Google Scholar 

  47. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Oestrogen replacement therapy in women with prior diagnosis and treatment of breast cancer. Gynecol Oncol 1997; 65: 89–93

    Article  PubMed  CAS  Google Scholar 

  48. Guidozzi F. Estrogen replacement therapy in breast cancer survivors. Int J Gyneacol Obstet 1999; 64: 59–63

    Article  CAS  Google Scholar 

  49. Espie M, Gorins A, Perret F, et al. Hormone replacement therapy (ERT) in patients treated for breast cancer: analysis of a cohort of 120 patients [abstract]. Proc Soc Clin Oncol 1999; 18: 586A

    Google Scholar 

  50. Brewster WR, DiSaia PJ, Grosen EA, et al. An experience with estrogen replacement in breast cancer survivors. Int J Fertil Womens Med 1999; 44: 186–92

    PubMed  CAS  Google Scholar 

  51. Bluming AZ, Waisman JR, Dosik GA, et al. Hormone replacement therapy (ERT) in women with previously treated primary breast cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20: 12B

    Google Scholar 

  52. DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494–8

    Article  PubMed  CAS  Google Scholar 

  53. Ursic-Vrscaj M, Bebar S. A case controlled study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999; 25: 146–51

    Article  PubMed  CAS  Google Scholar 

  54. O’Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754–62

    Article  PubMed  Google Scholar 

  55. Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effect on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001; 60: 199–206

    Article  PubMed  CAS  Google Scholar 

  56. Eden J, Bush T, Nand S, et al. The Royal Hospital for Women Breast Cancer Study: a case controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 1995; 2: 67–72

    Article  Google Scholar 

  57. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002; 177: 347–51

    PubMed  Google Scholar 

  58. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal oestrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6: 45–52

    PubMed  CAS  Google Scholar 

  59. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17: 1482–7

    PubMed  CAS  Google Scholar 

  60. Marsden J, Whitehead M, A’Hern R, et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000; 73: 292–9

    Article  PubMed  CAS  Google Scholar 

  61. Marttunen MB, Hietanen P, Pyrhonen S, et al. A prospective study on women with a history of breast cancer with or without oestrogen replacement therapy. Maturitas 2001; 39: 217–25

    Article  PubMed  CAS  Google Scholar 

  62. Von Schoultz E, Rutquist L. Menopausal therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97: 533–5

    Article  Google Scholar 

  63. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial amongst hysterectomized women. Lancet 1998; 352: 93–7

    PubMed  CAS  Google Scholar 

  64. Isaacs CJ, Swain SM. Hormone replacement therapy in women with a history of breast carcinoma. Haematol Oncol Clin North Am 1994; 8: 179–95

    CAS  Google Scholar 

  65. Dupont WD, Page DL, Rogers LW, et al.] Influence of exogenous oestrogens on proliferative breast disease. Cancer 1989; 63: 948–57

    Article  PubMed  CAS  Google Scholar 

  66. Loprinzi CL, Barton DL, Rhodes D. Prevention of hot flashes in breast cancer survivors. Lancet Oncol 2001; 2: 199–204199-204

    Article  PubMed  CAS  Google Scholar 

  67. Erlik Y, Meldrum DR, Lagasse LD, et al. Effect of megastrol acetate on flushing and bone metabolism in post menopausal women. Maturitas 1981; 3: 167–72

    Article  PubMed  CAS  Google Scholar 

  68. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–52

    Article  PubMed  CAS  Google Scholar 

  69. Bullock JL, Massey FM, Gambrell Jr RD. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975; 46: 165–8

    PubMed  CAS  Google Scholar 

  70. Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for the relief of climacteric symptoms. Am J Obstet Gynecol 1980; 138: 99–104

    PubMed  CAS  Google Scholar 

  71. Young RL, Kumar NS, Goldzieher JW. Management of menopause when oestrogen cannot be used. Drugs 1990; 40: 220–30

    Article  PubMed  CAS  Google Scholar 

  72. Graf M, Geller P. Treating hot flashes in breast cancer survivors: a review of alternative treatments to hormone replacement therapy. Clin J Oncol Nurs 2003; 7(6): 637–40

    Article  PubMed  Google Scholar 

  73. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002; 177: 347–51

    PubMed  Google Scholar 

  74. Longacre T, Barlow S. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382–93

    Article  PubMed  CAS  Google Scholar 

  75. Anderson TJ, Battersby S, King RJ, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989; 20: 1139–44

    Article  PubMed  CAS  Google Scholar 

  76. Huggins C, Yang N. Induction and extinction of mammary cancer. Science 1962; 137: 257–62

    Article  PubMed  CAS  Google Scholar 

  77. Kordon E, Lanari C, Meiss R, et al. Hormone dependence of a mouse mammary tumour line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 1990; 17(1): 33–45

    Article  PubMed  CAS  Google Scholar 

  78. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynecol 1999; 106: 1–21

    Article  CAS  Google Scholar 

  79. Pasqualini J. Differential effects of progestins on breast tissues. Maturitas 2003; 46S1: S45–54

    Article  CAS  Google Scholar 

  80. Kloosterboer HJ, Schoonen WG, Deckers GH, et al. Effects of progestogens and ORG OD12 in in vitro and in vivo tumour models. J Steroid Biochem Mol Biol 1994; 49: 311–8

    Article  PubMed  CAS  Google Scholar 

  81. Conner P. A comparative study of breast cell proliferation during HRT: effects of tibolone and continuous combined estrogen/progestin therapy. Climacteric 2004; 7(1): 50–8

    Article  PubMed  CAS  Google Scholar 

  82. Valdivia I, Campodonico I, Tapia A, et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in post menopausal women. Fertil Steril 2004; 81(3): 617–23

    Article  PubMed  CAS  Google Scholar 

  83. Wierik EJ, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined oestrogen and progestin therapies: a UK mediplus study. Climacteric 2004; 7(2): 197–209

    Article  PubMed  CAS  Google Scholar 

  84. Allen D, de Vries C, Farmer R, et al. Breast cancer and HRT: the GPRD Study. Pharmacoepidemiol Drug Saf 2002; 11: S138–9

    Google Scholar 

  85. Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004; 91(4): 644–50

    PubMed  CAS  Google Scholar 

  86. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG 2005; 112(2): 228–33

    Article  PubMed  CAS  Google Scholar 

  87. Bundred NJ, Turner LE. Postmenopausal hormone therapy before and after breast cancer: clinical experiences. Maturitas 2004; 49(1): S22–31

    Article  PubMed  CAS  Google Scholar 

  88. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen induced hot flashes. Ann Intern Med 2000; 132: 788–93

    PubMed  CAS  Google Scholar 

  89. Clayden JR, Bell JW, Pollard P. Menopausal flushing: Double blind trial of a non hormonal medication. BMJ 1974; 1: 409–12

    Article  PubMed  CAS  Google Scholar 

  90. Edington RF, Chagnon JP, Steinberg WM. Clonidine for menopausal flushing. CMAJ 1980; 5: 23–6

    Google Scholar 

  91. Wren B, Brown L. A double blind trial with Clonidine and a placebo to treat hot flushes. Med J Aust 1986; 144: 369–70

    PubMed  CAS  Google Scholar 

  92. Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen induced hot flashes. J Clin Oncol 1994; 12: 155–8

    PubMed  CAS  Google Scholar 

  93. Guttuso Jr TJ, Kurlan R, McDermott MP, et al. Gabapentin effects on hot flashes in post menopausal women: a randomized control trial. Obstet Gynecol 2003; 101: 337–45

    Article  PubMed  CAS  Google Scholar 

  94. Guttuso Jr TJ. Gabapentin effects on hot flushes and hypothermia. Neurology 2000; 54: 2161–3

    Article  PubMed  Google Scholar 

  95. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17–22

    Article  PubMed  CAS  Google Scholar 

  96. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16(7): 2377–81

    PubMed  CAS  Google Scholar 

  97. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356: 2059–63

    Article  PubMed  CAS  Google Scholar 

  98. Loprinzi CL, Sloan JA, Perez EA, et al. Phase 3 evaluation of Fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578–83

    Article  PubMed  CAS  Google Scholar 

  99. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized control trial. JAMA 2003; 289(21): 2827–34

    Article  PubMed  CAS  Google Scholar 

  100. Kimmick GG, Lovato J, McQuellon R, et al. Randomized placebo controlled study of sertraline (Zoloft™) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen [abstract]. Proc ASCO 2001; 20: 1585

    Google Scholar 

  101. Barton DL, Loprinzi CL, Sloan JA, et al. Pilot evaluations of newer antidepressants for hot flashes [abstract]. Proc ASCO 2002; 21: 1463

    Google Scholar 

  102. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction amongst newer antidepressants. J Clin Psychiatry 2002; 63: 357–66

    Article  PubMed  Google Scholar 

  103. Lawlor DA, Juni P, Ebrahim S, et al. Systematic review of the epidemiological and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003; 56: 155–63

    Article  PubMed  Google Scholar 

  104. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the SSRI paroxetine. J Natl Cancer Inst 2003; 95: 1758–64

    Article  PubMed  CAS  Google Scholar 

  105. Adlercreutz H, Mazur W. Phytoestrogens and western diseases. Am Med 1997; 29: 95–120

    CAS  Google Scholar 

  106. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of oestrogenic chemicals and phytoestrogens with oestrogen receptor beta. Endocrinology 1998; 139: 4252–63

    Article  PubMed  CAS  Google Scholar 

  107. Tham DM, Gardner CD, Haskell WL, et al. Clinical review 97: potential health benefits of dietary phytoestrogens. A review of the clinical, epidemiological and mechanistic evidence. J Clin Endocrinol Metab 1998; 83: 2223–35

    Article  PubMed  CAS  Google Scholar 

  108. Murkies AL, Wilcox G, Davis SR. Phytoestrogens: a review. J Clin Endocrinol Metab 1998; 83(2): 297–303

    Article  PubMed  CAS  Google Scholar 

  109. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6–11

    Article  PubMed  CAS  Google Scholar 

  110. van de Weijer P, Barentsen R. Isoflavones from red clover significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42(3): 187–93

    Article  PubMed  Google Scholar 

  111. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the isoflavone clover extract study: a randomized controlled trial. JAMA 2003; 290(2): 207–14

    Article  PubMed  CAS  Google Scholar 

  112. Krebs EE, Ensrud KE, MacDonald R, et al. Phytoestrogens for the treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004; 104: 824–36

    Article  PubMed  CAS  Google Scholar 

  113. Ingram D, Sanders K, Kolybaba M, et al. Case control study of phytoestrogens and breast cancer. Lancet 1997; 350: 990–4

    Article  PubMed  CAS  Google Scholar 

  114. Atkinson C, Warren RM, Sala E, et al. Red clover derived isoflavones and mammographic breast density: a double blind randomized placebo controlled trial. Breast Cancer Res 2004; 6: R170–9

    Article  PubMed  CAS  Google Scholar 

  115. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592–5

    PubMed  CAS  Google Scholar 

  116. Huntley A, Ernst E. A systematic review of herbal medicine products for the treatment of menopausal symptoms. Menopause 2003; 10: 465–76

    Article  PubMed  Google Scholar 

  117. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes amongst women with a history of breast cancer. J Clin Oncol 2001; 19: 2739–45

    PubMed  CAS  Google Scholar 

  118. Hernandez G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003; 44: S59–65

    Article  Google Scholar 

  119. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for the treatment of climacteric symptoms. Obstet Gynecol 2005; 105: 1074–83

    Article  PubMed  Google Scholar 

  120. Lindh-Astrand L, Nedstrand E, Wyon Y, et al. Vasomotor symptoms and quality of life in previously sedentary women randomized to physical activity or oestrogen therapy. Maturitas 2004; 15: 97–105

    Article  CAS  Google Scholar 

  121. Aiello EJ, Yasui Y, Tworoger SS, et al. Effect of a year long moderate intensity exercise intervention on the occurrence and severity of menopausal symptoms in post menopausal women. Menopause 2004; 11: 382–8

    Article  PubMed  Google Scholar 

  122. Freedman R, Woodward S. Behavioural treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167: 436–9

    PubMed  CAS  Google Scholar 

  123. Cohen SM, Rousseau ME, Carey BL. Can acupuncture relieve symptoms of the menopause. Holist Nurs Pract 2003; 17: 295–9

    PubMed  Google Scholar 

  124. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366(9488): 818–24

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Associate Professor Rodney Baber, through Royal North Shore Hospital, has participated in clinical trials sponsored by various pharmaceutical and complementary medicine companies. All funding for such trials has been directed to Royal North Shore Hospital managed accounts. He has also spoken at seminars sponsored by Organon, Novo Nordisk, Wyeth Ayerst, Eli Lilly, Novartis, Novogen and Servier Laboratories, for which he has had costs reimbursed. He is currently an investigator for the ‘LIBERATE’ trial.

No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Division of Women’s and Children’s Health, Royal North Shore Hospital of Sydney, Pacific Highway, St Leonards, Sydney, New South Wales, 2065, Australia

    Rodney Baber & Michelle Kwik

  2. The University of Sydney, Sydney, New South Wales, Australia

    Rodney Baber

  3. School of Women’s and Infants’ Health, King Edward Memorial Hospital Perth, The University of Western Australia, Perth, Western Australia, Australia

    Martha Hickey

Authors
  1. Rodney Baber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martha Hickey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelle Kwik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baber, R., Hickey, M. & Kwik, M. Therapy for Menopausal Symptoms During and After Treatment for Breast Cancer. Drug-Safety 28, 1085–1100 (2005). https://doi.org/10.2165/00002018-200528120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528120-00004

Keywords

Search

Navigation